Report to:	Trust Board (public)	Agenda item:	SFT 4020
Date of Meeting:	12 April 2018		

Committee Name:	Strategy Committee		Committee Meeting Date:	26 March 2018
Status:	Information	Discussion	Assurance	Approval
			X	
Prepared by:	Laurence Arnold, Director of Corporate Development			
Board Sponsor (presenting):	Tania Baker, Non-Executive Director and Committee Chairman			

Recommendation

To highlight key aspects of the Strategy Committee meeting of 26 March 2018 including adjustments to the Committee's Terms of Reference.

Items for Escalation to Board

The Strategic Committee held its first meeting on 26 March 2018. Being its inaugural meeting the Committee's business largely focused on its establishment and the approach to be taken to developing its agenda for the coming year.

Terms of Reference

The Committee reviewed its Terms of Reference and identified the following minor changes:

- To adjust the membership section to require two clinicians in attendance rather than as core members. This adjustment would reduce the impact of potential non-attendance on quoracy
- To insert text to reflect the overlap of the Committee's activities with the work of the Trust's Outstanding Every Time Board and the Finance & Performance Committee
- As each of the Committees of the Board have a role in reviewing related sections of the Board Assurance Framework (BAF) the Strategy Committee's terms of reference would be adjusted to incorporate a requirement for the Committee to review the general direction of the strategic objectives within the BAF and the RAG rating of these

Committee work plan and frequency of meetings

The Committee will next meet towards the end of April. At this meeting the Committee will be considering its work plan for the coming year and will agree its meeting frequency based on key milestones in the development of the Trust's clinical, estates and digital strategies.

It is envisaged that the April meeting will have a presentation and discussion on the ongoing clinical strategy work stream.